CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aktsnrny Krgnsky bshchstv Mdtsnskkh is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aktsnrny Krgnsky bshchstv Mdtsnskkh
pr. Konstitutsii, d.7
Phone: +7 4951375727p:+7 4951375727 KURGAN, 640008  Russian Federation Ticker: ksinksin

This company was Merged or Acquired on 5/26/2020.
On March 4, 2022, CreditRiskMonitor.com, Inc. suppressed the FRISK® score of all publicly listed Russian and Ukrainian-based companies trading domestically due to the closure of their respective stock markets. The halt of trading in a counterparty’s securities is never a positive signal for creditors or suppliers, but especially in situations where the prices of those securities were above book value before the halt. The loss of liquidity optionality from equity markets inherently increases the bankruptcy risks for any business and dealing with businesses who have lost this financing option should be strongly scrutinized. Stock Market data is one of the essential components used in the daily calculation of the FRISK®. The omission of this data can reduce the score's effectiveness in predicting bankruptcy risk for companies trading within these markets. In addition, any analysis based on previously reported financials should be used with caution in this environment. We are continuing to monitor the Russia-Ukraine conflict and plan to reevaluate the appropriateness of the FRISK® when the affected exchanges have reopened and trading in securities resumes.
This is a Subsidiary, click here for the Parent Company

Business Summary
Sintez PAO, a.k.a. Sintez PJSC, is a Russia-based pharmaceuticals manufacturer. The Company's product portfolio includes drugs such as AzitRus, Almorus, Amosin, Arlet, Atsekardol, Bifosin, Bitsillin, Bronhorus, Vankorus, Vedikardol, Leflobakt and Lofoks, among others. The Company produces tablets, capsules, ampoules, drops, creams, gels, and antibiotics, as well as plastic facilities for blood testing and transfusion, products for blood preservation, and medicines for veterinary use, among others.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Oleg S.Mubarakshin 53 7/5/2019 7/4/2019
Chairman of the Board Dmitry L.Zubov 65 12/24/2019 11/12/2019
General Director (CEO) of the Managing Company, Director of Legal Issues, Secretary to the Board of Soslan S.Gaboev 37 12/24/2019 1/1/2016
6 additional Officers and Directors records available in full report.

Business Names
Business Name
AKO medit. prep. i izdel. Sintez OAO (P)
KSIN
KSINP
Sintez OAO (P)

General Information
Number of Employees: 3,017 (As of 9/30/2013)
Outstanding Shares: 264,352 (As of 9/30/2022)
Shareholders: 2,218
Stock Exchange: RTB
Fax Number: +7 3522481608


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 14, 2024